High-precision determination of $g$ factors and masses of $^{20}\text{Ne}^{9+}$ and $^{22}\text{Ne}^{9+}$

Autor: Heiße, F., Door, M., Sailer, T., Filianin, P., Herkenhoff, J., König, C. M., Kromer, K., Lange, D., Morgner, J., Rischka, A., Schweiger, Ch., Tu., B., Novikov, Y. N., Eliseev, S., Sturm, S., Blaum, K.

We present the measurements of individual bound electron $g$ factors of $^{20}\text{Ne}^{9+}$ and $^{22}\text{Ne}^{9+}$ on the relative level of $0.1\,\text{parts}$ per billion. The comparison with theory represents the most stringent test of bound-s

Externí odkaz: http://arxiv.org/abs/2310.11119

$\text{Direct}~Q\text{-Value Determination of the}~\beta^-~\text{Decay of} ~^{187}\text{Re}$

Autor: Filianin, P., Lyu, C., Door, M., Blaum, K., Huang, W. J., Haverkort, M., Indelicato, P., Keitel, C. H., Kromer, K., Lange, D., Novikov, Y. N., Rischka, A., Schüssler, R. X., Schweiger, Ch., Sturm, S., Ulmer, S., Harman, Z., Eliseev, S.

Publikováno v: Phys. Rev. Lett. 127 (2021) 072502

The cyclotron frequency ratio of $^{187}\mathrm{Os}^{29+}$ to $^{187}\mathrm{Re}^{29+}$ ions was measured with the Penning-trap mass spectrometer PENTATRAP. The achieved result of $R=1.000\:000\:013\:882(5)$ is to date the most precise such measureme

Externí odkaz: http://arxiv.org/abs/2108.07039

Human organoids with an autologous tissue-resident immune compartment.

Autor: Recaldin T; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Steinacher L; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.; Hannover Medical School, Institute of Immunology, Hannover, Germany., Gjeta B; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.; University of Basel, Basel, Switzerland., Harter MF; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.; Gustave Roussy Cancer Campus, University Paris-Saclay, Paris, France., Adam L; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Kromer K; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Mendes MP; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Bellavista M; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Nikolaev M; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Lazzaroni G; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Krese R; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Kilik U; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland.; University of Basel, Basel, Switzerland., Popovic D; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Stoll B; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Gerard R; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Bscheider M; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Bickle M; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland., Cabon L; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland. lauriane.cabon@roche.com., Camp JG; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland. gray.camp@roche.com., Gjorevski N; Institute of Human Biology (IHB), Roche Pharma Research and Early Development, Basel, Switzerland. nikolche.gjorevski@roche.com.

Publikováno v: Nature [Nature] 2024 Sep; Vol. 633 (8028), pp. 165-173. Date of Electronic Publication: 2024 Aug 14.

Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.

Autor: Harter MF; Institute of Human Biology (IHB), Roche Innovation Center Basel, Basel, Switzerland.; Gustave Roussy Cancer Campus, University Paris-Saclay, Paris, France., Recaldin T; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Gerard R; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Avignon B; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bollen Y; Institute of Human Biology (IHB), Roche Innovation Center Basel, Basel, Switzerland., Esposito C; Department of Biomedicine, University of Basel, Basel, Switzerland., Guja-Jarosz K; Department of Biomedicine, University of Basel, Basel, Switzerland., Kromer K; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Filip A; Institute of Human Biology (IHB), Roche Innovation Center Basel, Basel, Switzerland., Aubert J; Institute of Human Biology (IHB), Roche Innovation Center Basel, Basel, Switzerland., Schneider A; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Bacac M; Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland., Bscheider M; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Stokar-Regenscheit N; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Piscuoglio S; Department of Biomedicine, University of Basel, Basel, Switzerland., Beumer J; Institute of Human Biology (IHB), Roche Innovation Center Basel, Basel, Switzerland., Gjorevski N; Institute of Human Biology (IHB), Roche Innovation Center Basel, Basel, Switzerland. nikolche.gjorevski@roche.com.

Publikováno v: Nature biomedical engineering [Nat Biomed Eng] 2024 Apr; Vol. 8 (4), pp. 345-360. Date of Electronic Publication: 2023 Dec 19.

H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.

Autor: Boschert T; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ, Mainz, Germany., Kromer K; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; BioMed X GmbH, Heidelberg, Germany., Lerner T; BioMed X GmbH, Heidelberg, Germany., Lindner K; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Immune Monitoring Unit, DKFZ and National Center for Tumour Diseases (NCT), Heidelberg, Germany., Haltenhof G; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Tan CL; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Jähne K; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Poschke I; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Immune Monitoring Unit, DKFZ and National Center for Tumour Diseases (NCT), Heidelberg, Germany., Bunse L; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany., Eisele P; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany., Grassl N; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany., Mildenberger I; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany., Sahm K; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany., Platten M; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ, Mainz, Germany.; Immune Monitoring Unit, DKFZ and National Center for Tumour Diseases (NCT), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany.; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim Germany., Lindner JM; BioMed X GmbH, Heidelberg, Germany., Green EW; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN Heidelberg University, Mannheim, Germany.

Publikováno v: Science advances [Sci Adv] 2024 Feb 02; Vol. 10 (5), pp. eadi9091. Date of Electronic Publication: 2024 Feb 02.